Compare VEON & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | NAMS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United Arab Emirates | Netherlands |
| Employees | N/A | 100 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 2010 | N/A |
| Metric | VEON | NAMS |
|---|---|---|
| Price | $53.11 | $32.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $73.40 | $46.75 |
| AVG Volume (30 Days) | 68.3K | ★ 761.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | $17.96 |
| Revenue Next Year | $1.60 | $540.65 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.55 | $16.79 |
| 52 Week High | $64.00 | $42.00 |
| Indicator | VEON | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 49.04 |
| Support Level | $51.66 | $29.73 |
| Resistance Level | $56.05 | $37.25 |
| Average True Range (ATR) | 1.72 | 1.66 |
| MACD | 0.65 | -0.02 |
| Stochastic Oscillator | 74.51 | 24.42 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.